ABVC BioPharma Inc. (ABVC)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ABVC Chart
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. ("OncoX") as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.1
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches.
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1.
ABVC BioPharma Inc. Dividends
ABVC BioPharma Inc. Earnings
| 15 May 2025 Date | | - Cons. EPS | - EPS |
| 11 Mar 2025 Date | | - Cons. EPS | - EPS |
| 13 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2025 Date | | - Cons. EPS | - EPS |
| 11 Mar 2025 Date | | - Cons. EPS | - EPS |
| 13 Nov 2024 Date | | - Cons. EPS | - EPS |
| 14 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
ABVC BioPharma Inc. (ABVC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ABVC BioPharma Inc. ever had a stock split?
ABVC BioPharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Uttam Yashwant Patil Ph.D. CEO | NASDAQ (CM) Exchange | 00091F106 Cusip |
| US Country | 16 Employees | - Last Dividend | 25 Jul 2023 Last Split | - IPO Date |
Overview
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company based in Fremont, California. It focuses on developing drugs and medical devices aimed at fulfilling unmet medical needs within the United States healthcare market. The company is dedicated to advancing a wide range of therapies across various stages of clinical trials, targeting diseases with high unmet medical needs including cancer, major depressive disorders, adult attention deficit hyperactivity disorder, myelodysplastic syndromes, and more. Operating as a subsidiary of YuanGene Corporation, ABVC BioPharma, Inc. has established co-development and collaboration agreements with Rgene Corporation, BioHopeKing Corporation, and BioFirst Corporation to bolster its research and development efforts.
Products and Services
- ABV-1501
Currently in Phase II clinical trials, ABV-1501 is a combination therapy aimed at treating triple negative breast cancer, a specific cancer subtype known for its lack of three common receptors found in other breast cancers.
- ABV-1504
ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. This development represents ABVC BioPharma’s efforts in addressing mental health conditions with effective treatment options.
- ABV-1505
In Phase II clinical trials, ABV-1505 is being studied for its potential to treat adult attention deficit hyperactivity disorder (ADHD), targeting adults who continue to suffer from or are diagnosed with ADHD later in life.
- ABV-1703
ABV-1703 is under Phase II clinical trials for treating metastatic pancreatic cancer, focusing on one of the most aggressive and deadly forms of cancer by seeking to improve outcomes and survival rates for patients.
- ABV-1702
Currently in Phase II clinical trials, ABV-1702 aims to treat myelodysplastic syndromes, a group of cancers in which immature blood cells in the bone marrow do not mature into healthy blood cells.
- ABV-1601
ABV-1601 is being tested in Phase I/II clinical trials for its potential to treat depression in cancer patients, targeting the emotional and psychological challenges faced by individuals battling cancer.
- ABV-1701 Vitargus
In Phase II clinical trials, ABV-1701 Vitargus is being developed for the treatment of retinal detachment or vitreous hemorrhage, aiming to improve treatment options for these serious eye conditions.
- ABV-1519
Currently in Phase I/II clinical trials, ABV-1519 is being developed to treat non-small cell lung cancer, one of the most common types of lung cancer, signaling ABVC BioPharma’s commitment to combatting this deadly disease.
Contact Information
